Working… Menu
Trial record 36 of 128 for:    Venetoclax AND complete response

Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02427451
Recruitment Status : Recruiting
First Posted : April 28, 2015
Last Update Posted : May 22, 2019
Information provided by (Responsible Party):
Kerry Rogers, Ohio State University Comprehensive Cancer Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : August 29, 2019
Estimated Study Completion Date : August 29, 2020